#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

A mouse and cell study linked tirzepatide with less liver fat and inflammation, with Dectin-1 signaling proposed as part of the mechanism.

A 2026 South Korean cohort linked semaglutide and liraglutide initiation with selected safety outcomes, without proving causation.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.

One patient taking tirzepatide completed 17 ECT sessions without complications, but the case report cannot establish a safe protocol.

Two patients reported fewer migraine days on tirzepatide, but weight loss and an uncontrolled design prevent causal conclusions.

A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.

A preclinical mouse study found more fat loss with vutiglabridin plus semaglutide, but it provides no evidence of human efficacy.

A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.

A 2026 paper describes reported oral and salivary symptoms with incretin medicines, but it does not establish causation for tirzepatide.

A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.

A 2026 review asks why GIP receptor agonists and blockers can both support weight loss, then separates mouse mechanisms from human trial evidence.